Amylin Pharmaceuticals, Inc. http://www.alacrastore.com/company-snapshot/Amylin_Pharmaceuticals_Inc-1057635 Wednesday, October 08, 2008 4:50:16 AM 1057635 Amylin Pharmaceuticals, Inc. en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/newstex/PRN-0005-28299723newstex/PRN-0005-28299723xml SAN DIEGO, Sep. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders,...040000000401600007000000070050000400200004002006070150000701500307014000070140120700100007001007070030000700300113000000130010001300100213010000130100059/25/2008 9:27:13 AM1800000018007000PR Newswire USPRN-0005-28299723AMYLIN PHARMACEUTICALS INCENTEROMEDICS INCLILLY ELI & COAMLNETRMLLYNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1933170ccbn/T1933170norm... - Morgan Stanley - AnalystAll right, I think we're going to start now. We're into our -- up here, next up, we have Amylin Pharmaceuticals. Thanks, everybody, for joining us. I'm sure we'll have a lot of questions here. So we want to make this as interactive as possible. So, Dan Bradbury, CEO of the Company. We also have Jeff joining us from Investor Relations. I'm going to just start with the first question. I'm going to just make it relatively broad. And there's been a lot going on in the last, say, three to six months in the company both around LAR as well as the concerns with Byetta and safety. Give us a little bit of your view, an overview here of where you stand with the Byetta franchise on both the commercial side and the regulatory front and what you see playing out in the next # to ## months. ... 9/10/2008 10:05:00 AMAmylin Pharmaceuticals, Inc.54.0000FinalAmylin Pharmaceuticals, Inc. at Morgan Stanley Global Healthcare Unplugged Conference TranscriptAMLN10:55am ETTranscriptT1933170Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1925225ccbn/T1925225norm... - BioCentury - Senior Writer Good morning. I'm Stacy Lawrence, a senior writer with BioCentury. Our next presenting company is Amylin, which is expanding its diabetes franchise through sales of Byetta and Symlin for type II diabetes. In the first half of next year, the Company is planning to submit an NDA for once-weekly exenatide in type II diabetes plus has Phase IIIb data in type II diabetes. Amylin is looking for Phase IIb data in obesity in the second half of next year. Presenting for Amylin is CFO Mark Foletta. We're going to actually keep the breakout session in this room. So we'll have, I think, a brief ##, ## minutes for questions immediately following. Thank you. ... 9/5/2008 1:04:00 PMAmylin Pharmaceuticals, Inc.54.0000FinalAmylin Pharmaceuticals Inc. at NewsMakers in the Biotech Industry TranscriptAMLN11:30am ETTranscriptT1925225Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/B1935965ccbn/B1935965norm...AMLN announced that on ##/##/## FDA issued an update to a prior alert for BYETTA, an injectable medication prescribed for patients with type # diabetes. ... 8/26/2008 8:05:00 PMAmylin Pharmaceuticals, Inc.54.0000EditedAmylin FDA Update on Byetta SummaryAMLN2:00pm PTBriefB1935965Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1935965ccbn/T1935965norm...Good afternoon. Welcome to Amylin Pharmaceuticals and Eli Lilly and Company's conference call to provide context around the recent FDA alert for BYETTA. Our discussion today will not include updates on other aspects of our businesses. Today's discussion will contain forward-looking statements that involve risk and uncertainties. These risks and uncertainties are outlined in our recent filings with the Securities and Exchange Commission. Our actual results could differ materially from what is discussed on today's call. In addition, the information we provide is not intended to be promotional and is not sufficient for prescribing decisions. Prescribers should refer to the BYETTA package insert for complete safety information and current prescribing information. If you are a patient and would like additional information, please visit www.BYETTA.com or call the Amylin-Lilly customer support center toll-free at #-###-###-####. Let me introduce the other members of the Amylin and Lilly management... 8/26/2008 6:05:00 PMAmylin Pharmaceuticals, Inc.54.0000FinalAmylin FDA Update on Byetta TranscriptAMLN2:00pm PTTranscriptT1935965Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/B1898886ccbn/B1898886norm...Consistent with goal of creating co. that can increase shareholder value over time by producing sustainable growth. ... 7/25/2008 6:07:00 AMAmylin Pharmaceuticals, Inc.54.0000EditedQ2 2008 Amylin Pharmaceuticals, Inc. Earnings Conference Call SummaryAMLN2:00pm PTBriefB1898886Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26813924newstex/PRN-0005-26813924xml SAN DIEGO, Jul. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended June ##, ####. The Company reported total revenue of $###.#...070000000700500004000000040020000400200604016000040160180401604804016001040100000401000107014000070140120701401407003000070030011300000013010000130100057/21/2008 5:17:51 PM180000001800400018008000180200001801200019000000190010001900200019002007PR Newswire USPRN-0005-26813924AMYLIN PHARMACEUTICALS INCDANIEL BRADBURYAMLNNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1898886ccbn/T1898886norm...Good day, ladies and gentlemen and welcome to your Amylin Pharmaceutical second quarter earnings call. At this point, all attendees are in the listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. I would now like to turn the call over to Michael York, Senior Director of Finance. Sir, you may begin. ... 7/21/2008 5:05:00 PMAmylin Pharmaceuticals, Inc.54.0000FinalQ2 2008 Amylin Pharmaceuticals, Inc. Earnings Conference Call TranscriptAMLN2:00pm PTTranscriptT1898886Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26681523newstex/PRN-0005-26681523xml SAN DIEGO, Jul. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will Webcast its Quarterly Update Conference Call for the second quarter of #### on Monday, July ##, #### at #:## p.m....0700000007014000070140120700300007003001040000000400200004002006040160000401604804016018040160011300000013010000130100057/15/2008 5:21:41 PM180000001800400018008000PR Newswire USPRN-0005-26681523AMYLIN PHARMACEUTICALS INCDANIEL BRADBURYAMLNNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1871936ccbn/T1871936norm... - Goldman Sachs - AnalystWell, good afternoon, everyone. Welcome back. I'm Meg Malloy on the biotech team and we're delighted this afternoon to have management of Amylin. This has been an interesting time for Amylin. They have launched two novel agents in diabetes over the last couple of years, which you all know about: Byetta, the first GLP# to enter the diabetes market, and also Symlin, which is used as an adjunct with insulin in treating diabetes. It's very timely to be able to sit down with Amylin because we are coming off the heels of the diabetes meeting just held up in San Francisco, so a lot of new data, a lot of new focus coming out of that and I'm sure we'll have a good opportunity to delve into that in the Q&A portion. So we're delighted to welcome back Dan Bradbury, who is the Chief Executive Officer of Amylin, who many of you know. We're going to follow our standard format, so Dan will make some opening comments and provide an overview and then we'll open it up to Q&A. So,... 6/13/2008 9:05:00 AMAmylin Pharmaceuticals, Inc.54.0000FinalAmylin Pharmaceuticals, Inc. at Goldman Sachs Healthcare Conference TranscriptAMLN1:20pm PTTranscriptT1871936Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1868325ccbn/T1868325norm... - Amylin Pharmaceuticals - President, CEO Good evening. I'd like to welcome you to our presentation this evening. My name is Dan Bradbury and I'm the President and Chief Executive Officer of Amylin and I'm very pleased to be here. I want to say thank you to all of you for your attendance tonight and for your interest in our Company. Before I start, a reminder that most of the comments I'll be making today will be about future plans for our organization. I intend to make a number of forward-looking statements, so please consult our filings with the SEC for a description of our risks. Now this evening I will provide a brief overview of Amylin as a Company and how we tackle the growing and related pandemics of diabetes and obesity. And then I'm very pleased that Dr. Steven Smith, Professor and Assistant Executive Director of Clinical Research at the Pennington Biomedical Research Center in Baton Rouge, Louisiana -- go Tigers -- will be giving an overview of the clinical data presented here... 6/10/2008 11:00:00 AMAmylin Pharmaceuticals, Inc.54.0000FinalAmylin Pharmaceuticals Investor Reception and Presentation TranscriptAMLN7:45pm PTTranscriptT1868325Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1862964ccbn/T1862964norm... - Amylin - Chairman of the Board Good morning. I'm Joe Cook, Chairman of the Board and a Director of Amylin Pharmaceuticals and I'm happy to welcome you to the Amylin Pharmaceuticals #### Annual Shareholders Meeting. Before I call the meeting to order, I'd like to introduce to you the members of the Board of Directors and the executive team who are with us today. Please stand as your name is called. Board members present today are Steve Altman, Theresa Beck, Dan Bradbury, Karin Eastham, Ginger Graham, Ted Green, Dr. Jay Skyler, I believe he's in the back, he is, Joe Sullivan, and Jim Wilson. In addition, Mark Foletta, our Senior Vice President and Chief Financial Officer is here, Mark? Orville Kolterman, Senior Vice President and Head of Development. And both of them will be available after the meeting to answer questions you may have. I would also like the rest of the officers of the Company to please stand up. Finally, I'd like to introduce [John Belly], with Ernst and Young, the Company's... 6/2/2008 3:05:00 PMAmylin Pharmaceuticals, Inc.54.0000FinalAmylin Pharmaceuticals, Inc. Shareholders Meeting TranscriptAMLN11:00am PTTranscriptT1862964Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1859077ccbn/T1859077norm... - Friedman Billings Ramsey Capital Markets - AnalystOkay, let's go ahead and get started with the next presentation. Thanks, everybody, for attending the ##th Annual FBR Spring Conference. It's good to see so many people here to see the next presentation and that's because this company is exciting and has a lot of interesting things going on, especially even here in the near term with diabetes about to be the center of investor's focus at the American Diabetes Association meeting in a couple weeks. And that -- since we're very excited to hear from a very granular executive at the Company and that's David Kendall, who is Executive Director of Medical Affairs. So, thanks again, David, for joining us and thanks for -- ... 5/29/2008 4:04:00 PMAmylin Pharmaceuticals, Inc.54.0000FinalAmylin Pharmaceuticals, Inc. at Friedman Billings Ramsey Capital Markets Spring Investor Conference TranscriptAMLN9:45am ETTranscriptT1859077Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1849707ccbn/T1849707norm... - Robert W. Baird & Co., Inc. - AnalystI'm Tom Russo, one of Baird's Biotech Analyst, and it's a pleasure to welcome for the first time to our Growth Stock Conference Amylin. Presenting on behalf of the Company is Chief Financial Officer, Mark Foletta. ... 5/20/2008 12:04:00 PMAmylin Pharmaceuticals, Inc.54.0000FinalAmylin Pharmaceuticals, Inc. at Robert W. Baird & Co., Inc. Growth Stock Conference TranscriptAMLN3:05pm CTTranscriptT1849707Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1846318ccbn/T1846318norm... - Bank of America - AnalystThank you for joining us today -- this morning for the first day Bank of American Las Vegas Healthcare Conference. My name is William Ho. I'm one of the senior biotech analysts here at B of A, and I do cover Amylin. I do have the pleasure today of introducing to you Michael York, Senior Director of Investor Relations, as well as [Jeffrey Ding]. And I'm just going to apologize for those of you in the audience, I am taking notes and not actually emailing with my BlackBerry. But with that, I'd like to introduce Michael York. ... 5/14/2008 6:06:00 PMAmylin Pharmaceuticals, Inc.54.0000FinalAmylin Pharmaceuticals, Inc. at Bank of America Securities Health Care Conference TranscriptAMLN10:00am PTTranscriptT1846318Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1816799ccbn/T1816799norm... - Morgan Stanley - AnalystThanks, everybody, for joining us. We now have a late, but intact Dan Bradbury from Amylin Pharmaceuticals joining us, who just had a tough time coming across the country. I appreciate you making it here and for a company that we've given a hard time to for how much money you burn, it's nice to see that you are flying commercial and not on a private plane. ... 5/2/2008 2:05:00 PMAmylin Pharmaceuticals, Inc.54.0000FinalAmylin Pharmaceuticals, Inc. at Morgan Stanley 2008 Global Healthcare Unplugged Conference TranscriptAMLN3:00pm ETTranscriptT1816799Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/B1821674ccbn/B1821674norm...Made steady progress across near, mid and long-term opportunities, executing against the strategy that Co. detailed earlier this year to build AMLN's diabetes portfolio and establish its presence in obesity field. ... 4/21/2008 2:04:00 PMAmylin Pharmaceuticals, Inc.54.0000EditedQ1 2008 Amylin Pharmaceuticals, Inc. Earnings Conference Call SummaryAMLN8:30am ETBriefB1821674Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1821674ccbn/T1821674norm...At this time, I would like to welcome everyone to the Amylin Pharmaceuticals, Incorporated, Q# earnings conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks to there will be a question-and-answer session. (OPERATOR INSTRUCTIONS) Thank you. And now I would like to turn the call over to Michael York, Senior Director of Investor Relations. Please go ahead, sir. ... 4/21/2008 12:04:00 PMAmylin Pharmaceuticals, Inc.54.0000FinalQ1 2008 Amylin Pharmaceuticals, Inc. Earnings Conference Call TranscriptAMLN8:30am ETTranscriptT1821674Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1756107ccbn/T1756107normAmylin Pharmaceuticals, Inc. at Merrill Lynch ##th Global Pharmaceutical, Biotechnology & Medical Device Conference2/7/2008 12:07:00 PMAmylin Pharmaceuticals, Inc.54.0000FinalAmylin Pharmaceuticals, Inc. at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference TranscriptAMLN1:00pm ETTranscriptT1756107Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/B1744071ccbn/B1744071norm1/28/2008 9:05:00 PMAmylin Pharmaceuticals, Inc.54.0000EditedQ4 2007 Amylin Pharmaceuticals, Inc. Earnings Conference Call SummaryAMLN2:00pm PT...In ####, BYETTA and SYMLIN continued to experience growth in physician adoption and prescriptions, generating net product sales of over $###m. ... BriefB1744071Credit & Investment ResearchThomson StreetEvents